Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2020 Apr 30:rs.3.rs-25643. [Version 1] doi: 10.21203/rs.3.rs-25643/v1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.

PMC Copyright notice

Overview of the workflow to identify candidate repurposable drugs to combat COVID-19. A) Drugs that are currently in use to treat coronavirus and putative COVID-19 treatments were clustered based on mechanism of action, ATC class and structural similarity. B) Gene expression data of the 978 genes that comprise the Library of Integrated Network-Based Cellular Signature (iLINCS) L1000 genes were extracted from severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome- related coronavirus (MERS) (GSE56192) transcriptomic datasets. C) Consensus iLINCS gene signatures were generated for drug groupings and disease. D) Connectivity analysis was conducted and a list of chemical perturbagens that are concordant (≥ 0.321 concordance) to the drug target grouping signatures or discordant (≤ − 0.321 discordance) to the disease signatures was generated. Chemical perturbagens are curated to identify top candidate drugs. E) Biological pathways of drug target groupings, disease signatures and candidate drugs was conducted. F) Fourteen perturbagens with concordance scores ≥ 0.8 in MCF7 and HA1E cell lines were shortlisted as repurposable candidate drugs.

Overview of the workflow to identify candidate repurposable drugs to combat COVID-19. A) Drugs that are currently in use to treat coronavirus and putative COVID-19 treatments were clustered based on mechanism of action, ATC class and structural similarity. B) Gene expression data of the 978 genes that comprise the Library of Integrated Network-Based Cellular Signature (iLINCS) L1000 genes were extracted from severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome- related coronavirus (MERS) (GSE56192) transcriptomic datasets. C) Consensus iLINCS gene signatures were generated for drug groupings and disease. D) Connectivity analysis was conducted and a list of chemical perturbagens that are concordant (≥ 0.321 concordance) to the drug target grouping signatures or discordant (≤ − 0.321 discordance) to the disease signatures was generated. Chemical perturbagens are curated to identify top candidate drugs. E) Biological pathways of drug target groupings, disease signatures and candidate drugs was conducted. F) Fourteen perturbagens with concordance scores ≥ 0.8 in MCF7 and HA1E cell lines were shortlisted as repurposable candidate drugs.